Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829843 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL17688155 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2548198 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL14268316 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL7273258 | 1.00 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL931109 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4144733 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL927049 | 0.95 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12908138 | 0.92 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL12238524 | 0.92 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057966-B1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS SPA (IT) | 2017-07-26 | — | — | EP | claimed |
| US-9518047-B2 | Process for the industrial synthesis of lurasidone | PROCOS S.P.A. (IT) | 2016-12-13 | — | — | US | claimed |
| EP-3057966-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | Procos S.p.A. (IT) | 2016-08-24 | — | — | EP | claimed |
| US-20160237077-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS S.P.A. (IT) | 2016-08-18 | — | — | US | claimed |
| US-9409899-B2 | Process for preparing benzisothiazol-3-yl-piperazin-1-yl-methyl-cyclo hexylmethanisoindol-1,3-dione and its intermediates | CADILA HEALTHCARE LIMITED (IN) | 2016-08-09 | — | — | US | claimed |
| WO-2015056205-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | PROCOS S.P.A. (IT) | 2015-04-23 | — | — | WO | claimed |
| EP-4463455-B1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LTD (IN) | 2026-04-29 | — | — | EP | disclosed |
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-08-19 | — | — | US | disclosed |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| EP-4463455-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | Suven Life Sciences Limited (IN) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023135528-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023135528-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2023-07-20 | — | — | WO | disclosed |
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | JD BIOSCIENCE INC. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | DAINIPPON SUMITOMO PHARMA CO, LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | DAINIPPON SUMITOMO PHARMA CO, LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. | 2011-01-06 | — | — | US | disclosed |
| US-5780632-A | Imide derivatives and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| EP-0464846-B1 | Imide derivatives, and their production and use | SUMITOMO PHARMA (JP) | 1998-04-22 | — | — | EP | disclosed |
| US-5532372-A | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0464846-A1 | Imide derivatives, and their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002349-A1 | TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TPH1, SLC6A4, TPH2 | KDM4E 3463/4885USP2 4248/4885ALDH1A1 714/4885 |
| US-12391698-B2 | Substituted piperidines and piperazines and methods for the treatment of CNS disorders | GRIN2C, SLC1A2, CNR2 | KDM4E 3587/4885USP2 3398/4885ALDH1A1 856/4885 |
| US-20250092049-A1 | HETEROALICYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | GRIN2C, CNR2, INA | KDM4E 3897/4885USP2 3766/4885ALDH1A1 1577/4885 |
| US-20110003994-A1 | CYCLOALKANE DERIVATIVE | CNR2, CNR1, OPRK1 | KDM4E 3129/4885USP2 1185/4885ALDH1A1 773/4885 |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | KDM4E 774/4885USP2 785/4885ALDH1A1 3570/4885 |
| US-20160237077-A1 | PROCESS FOR THE INDUSTRIAL SYNTHESIS OF LURASIDONE | REN, DCXR, ADRA1D | KDM4E 1985/4885USP2 2336/4885ALDH1A1 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.